Glenmark Q3 profit rises 16% on strong India, US performance
Glenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performance and margin expansion, with EBITDA surging 45% and regulatory clearance enabling manufacturing restart at its US facility.